Iteos Home

Pipeline

Home / Pipeline

Cancer immunotherapies by design, and in development.

Our two clinical-stage product candidates, EOS-448 and Inupadenant, each target a key mechanism that inhibits an effective antitumor immune response: a novel checkpoint TIGIT and the ATP adenosine pathway, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.

More about our pipeline

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

Preclinical

Phase 1

Phase 2a

Randomized

Registration-directed

EOS-448

+ dostarlimab | Solid Tumors

Phase 1, dosing

+ dostarlimab | 1L NSCLC PDL1high

Registration-directed, non-dosing

+ dostarlimab | HNSCC

Registration-directed, non-dosing

+ dostarlimab | Undisclosed

Registration-directed, non-dosing

+ dostarlimab + CD96 | Solid Tumors

Phase 1, non-dosing

+ dostarlimab + Inupadenant | Solid Tumors

Phase 1, non-dosing

+ Inupadenant | PD-1 Resistant Melanoma

Phase 1, dosing

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

Phase 2a, dosing

Inupadenant

Monotherapy | Evaluating Patient and Indication Selection Biomarkers

Phase 2, dosing

+ pembrolizumab | PD-1 Resistant Melanoma

Phase 2, dosing

+ chemotherapy | Post-IO mNSCLC

Randomized, non-dosing

EOS-984

IND Enabling Studies

Preclinical, dosing

Studies with dark backgrounds are dosing patients. Studies with light backgrounds have not yet dosed patients.

Child kissing older woman on cheek.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.

We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.